Myocardial protective effects of the phosphodiesterase 3 inhibitor, cilostazol, in streptozotocin-induced diabetic rats were investigated. Four weeks after induction of diabetes, we measured thrombospondin-1 (TSP-1) expression in the left ventricular myocardium. Microstructural and ultrastructural changes were also analysed. Four weeks after the induction of diabetes there were significant differences in body weight and blood glucose between the control, diabetic and cilostazol-treated diabetic animals. TSP-1 expression was significantly increased in the myocardium of diabetic rats compared with the control group. Although significantly higher than the control group, TSP-1 expression was significantly lower in the cilostazol group compared with the diabetes group. There were obvious ultrastructural changes in the myocardium of diabetic rats, which were rarely seen in cilostazol-treated diabetic rats. In conclusion, this study provides experimental evidence that cilostazol treatment of diabetic rats effectively prevents pathological myocardial alterations, possibly via the down-regulation of TSP-1 expression.
WestermannDVan LinthoutSDhayatS: Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol2007; 102: 500–507.
9.
ChenHHerndonMELawlerJ: The cell biology of thrombospondin-1. Matrix Biol2000; 19: 597–614.
10.
ZhangXMShenFXvZY: Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats. Int J Cardiol2005; 105: 192–197.
11.
GaoLWangFWangB: Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-κB-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther2006; 318: 53–58.
12.
HittelNDonnellyR: Treating peripheral arterial disease in patients with diabetes. Diabetes Obes Metab2002; 4 (suppl): S26–S31.
13.
KoikeNTakamuraTKanekoS: Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. Life Sci2007; 80: 1721–1728.
14.
ZhouJWangLLingS: Expression changes of growth-associated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats. Exp Neurol2007; 206: 201–208.
15.
WengYShenFLiJ: Expression changes of mitogen-activated protein kinase phosphatase-1 (MKP-1) in myocardium of streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes2007; 115: 455–460.
16.
AkulaAKotaMKGopisettySG: Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats. Pharmacol Res2003; 48: 429–435.
17.
DagliMGoksuNEryilmazA: Expression of histamine receptors (H1, H2, and H3) in the rabbit endolymphatic sac: An immunohistochemical study. Am J Otolaryngol2008; 29: 20–23.
18.
CharvatJMichalovaKChlumskyJ: The association between left ventricle diastolic dysfunction and endothelial dysfunction and the results of stress myocardial SPECT in asymptomatic patients with type 2 diabetes. J Int Med Res2005; 33: 473–482.
19.
AdamsJCLawlerJ: The thrombospondins. Int J Biochem Cell Biol2004; 36: 961–968.
20.
BreitkopfKSawitzaIWesthoffJH: Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells. Gut2005; 54: 673–681.
21.
MontagnaniMGolovchenkoIKimI: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem2002; 277: 1794–1799.
22.
BujakMFrangogiannisNG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res2007; 74: 184–195.
23.
HuangJQinGHHuCX: Effects of transforming growth factor-beta 1 and signal protein Smad3 on rat cardiomyocyte hypertrophy. Chin Med J (Engl)2004; 117: 1471–1475.
24.
YeJLinXMaC: The change of transforming growth factor-beta1 in nonproliferation diabetic retinopathy. Yan Ke Xue Bao2006; 22: 14–16 [in Chinese].
25.
SaltisJBobikA: Regulation by protein kinase C of transforming growth factor-beta 1 action on the proliferation of vascular smooth muscle cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol1996; 23: 573–575.
26.
TadaHKubokiKNomuraK: High glucose levels enhance TGF-β1–thrombospondin-1 pathway in cultured human mesangial cells via mechanisms dependent on glucose-induced PKC activation. J Diabetes Complications2001; 15: 193–197.
27.
OmiHOkayamaNShimizuM: Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res2004; 68: 119–125.
28.
SudoTItoHKimuraY: Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets2003; 14: 381–390.
29.
ItoCKusanoEAkimotoT: Cilostazol enhances IL-1β-induced NO production and apoptosis in rat vascular smooth muscle via PKA-dependent pathway. Cellular Signal2002; 14: 625–632.
30.
MatsumotoTKobayashiTWakabayashiK: Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol2005; 289: H1933–H1940.
